|
Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient Infected with SARS-CoV-2 Infection
Gad Allah Ali1, Majed Altareb2, Naeem Chaudhri3, Feras Abdulaziz Alfraih4
1 Hematology Fellow, Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Centre, Oncology Centre, Riyadh, KSA
2 Assistant Consultant, Adult Hematology and Stem Cell Transplant, Oncology Centre (MBC-64), Riyadh, KSA
3 Consultant, Adult Hematology/HSCT, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
4 President, Saudi Society for Blood Disorders, Director, Alternate Donor Stem Cell Transplant, Attending Physician, Adult Hematology/HSCT, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Correspondence Address:
Dr. Gad Allah Ali
Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh
KSA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joah.joah_10_21
|
|
The current coronavirus disease 2019 (COVID 19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. The full impact of the COVID 19 pandemic, caused by the SARS CoV 2, on the field of hematopoietic cell transplantation (HCT) is unknown. Here, we report a rare case of a 21-year-old male patient known to have chronic myeloid leukemia (CML) with progression to T-cell lymphoblastic lymphoma as extramedullary blast crisis of CML. The patient was treated by pediatric chemotherapy regimen then. He underwent haploidentical stem cell transplantation. Posttransplantation, on day +7, he developed SARS-CoV-2 after receiving stem cell graft from a donor who was diagnosed with SARS-CoV-2 on the day of stem cells harvesting. The case elaborates complications and outcome of a patient receiving stem cell transplant from a donor with SARS-CoV-2 infection.
|
